Last reviewed · How we verify
Apremilast Modified Release 11 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Apremilast Modified Release 11 (Apremilast Modified Release 11) — Amgen.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Apremilast Modified Release 11 TARGET | Apremilast Modified Release 11 | Amgen | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Apremilast Modified Release 11 CI watch — RSS
- Apremilast Modified Release 11 CI watch — Atom
- Apremilast Modified Release 11 CI watch — JSON
- Apremilast Modified Release 11 alone — RSS
Cite this brief
Drug Landscape (2026). Apremilast Modified Release 11 — Competitive Intelligence Brief. https://druglandscape.com/ci/apremilast-modified-release-11. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing